Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Ray Moynihan Australian Financial
Review, GPO Box 506, Sydney 2201, NSW, Australia Correspondence to: R
Moynihan, 4/1312 21st Street NW, Washington, DC, 20036, USA raymond.moynihan@verizon.net
| The first 150 words of the full text of this article appear below. |
Is a new disorder being identified to meet unmet needs or to build markets for new medications?
The corporate sponsored creation of a disease is not a new phenomenon,1 but the making of female sexual dysfunction is the freshest, clearest example we have. A cohort of researchers with close ties to drug companies are working with colleagues in the pharmaceutical industry to develop and define a new category of human illness at meetings heavily sponsored by companies racing to develop new drugs. The most recent gathering, featured Pfizer as chief sponsor and Pfizer-friendly researchers as chief speakers. The venue? The Pfizer Foundation Hall for Humanism in Medicine at New York University Medical School.
Since the launch of sildenafil (Viagra) in 1998, more than 17 million
men have had prescriptions written for it as a treatment for erectile
dysfunction, with Pfizer reporting sales in 2001 of
$1.5bn.2 The emerging competitors, Bayer's vardenafil and
Read all Rapid Responses